InvestorsHub Logo
Followers 22
Posts 888
Boards Moderated 0
Alias Born 05/09/2012

Re: runninggirl2016 post# 216361

Thursday, 02/08/2018 7:42:50 AM

Thursday, February 08, 2018 7:42:50 AM

Post# of 403217
Thanks runninggirl2016 for the reminder!

Bertolino Sept. 2017........


What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “If that is indeed the case in any number of patients, we will have compelling evidence to move forward expeditiously. A next step would be to complete development of an oral formulation of Kevetrin, which is the preferred delivery method of patients and facilitates the potential for multiple daily doses.”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News